Item 7.01 Regulation FD Disclosure.
On September 23, 2021, the Company issued a
press release, which is attached hereto as Exhibit 99.1, announcing multiple senior leadership appointments and promotions including
Arun Swaminathan, Ph.D., as Chief Business and Commercial Officer, Paul Diamond, Ph.D., as Vice President, Patent and Legal Counsel,
and the promotion of Avinash Desai, M.D., to the position of Chief Medical Officer from his previous position of Executive Vice
President, Clinical Development, Operations, and Medical Affairs. The Company undertakes no obligation to update, supplement or
amend the materials attached hereto as Exhibit 99.1.
Dr. Swaminathan is a highly accomplished executive
with over 20 years of experience in the global biopharmaceutical industry, which has included increasing positions of responsibility across
commercial, business development, and clinical roles. He has a proven track record of converting great science into successful business
opportunities. Prior to joining Actinium, Dr. Swaminathan was the Chief Business Officer and Senior Vice President at Alteogen Inc. a
South Korea-based biopharmaceutical company that focuses on the development and commercialization of novel biologics. In this role, his
negotiations with partners led to deals totaling over $6 billion in potential value, including agreements with two of the top ten global
pharmaceutical companies. During his tenure at Alteogen, the Company’s market value increased from approximately $400 million to
over $4 billion. Dr. Swaminathan joined Alteogen after they entered into an agreement with Lynkogen Inc. and gained full rights to develop
the assets. As CEO and co-founder of Lynkogen, he raised capital, in-licensed potentially transformative drug candidates to address complex
metabolic diseases and advanced Lynkogen from concept to a pre-clinical stage company with a lead drug candidate ready for IND enabling
studies that he successfully negotiated for out-licensing. Previously, Dr. Swaminathan held commercial and business development roles
at Bristol Myers Squibb over 12 years during two tenures, most recently as Worldwide Brand Director, where he managed products with over
$2 billion in annual sales across the top 10 global markets. Earlier at BMS, Dr. Swaminathan advanced from principal scientist to associate
director, working on approved products including Nulojix®, Orencia® and Eliquis®. Between his tenures at BMS, he spent nearly
four years at Covance (now Labcorp Drug Development), where he rose to Marketing Head, in charge of a $1 billion clinical business. Dr.
Swaminathan received his Ph.D., Pharmaceutical Sciences at the University of Pittsburgh, and is a graduate of the Marketing Management
Program at Wharton, University of Pennsylvania.
Dr. Diamond joins Actinium with over 20 years
of experience in patent law, developing and executing IP strategy within the biotechnology industry. He joins Actinium from Enzo Biochem,
Inc., where he was Senior Counsel, Patents and Business Development. As Enzo’s sole patent attorney and senior-most counsel, he
reported to the CEO and led all IP related and essential in-house legal functions. During his time at Enzo, Dr. Diamond obtained critical,
high-value patent coverage for key products and technologies and managed high-profile litigations and settlement negotiations that resulted
in a number of sizeable settlements. Prior to Enzo, Dr. Diamond first practiced IP law at global law firm White & Case LLP before
opening his own practice, Diamond Law Office, LLC, where he was of counsel to the firms Lucas & Mercanti, LLP and Zuber, Lawler &
Del Duca, LLP. Paul received his law degree from Fordham University School of Law. He also has a strong scientific background, receiving
a B.A. in Biology from The Johns Hopkins University and a Ph.D. in Molecular and Cellular Biology from Harvard University.
Dr. Desai is a hematologist/oncologist with nearly
25 years of drug development industry experience. Over the course of his career, Dr. Desai has successfully designed and implemented clinical
development, U.S. and global medical affairs, and life cycle management plans for a variety of pharmaceutical products. This has included
participation in multiple INDs, NDAs, and sNDA submissions and efficiently managing the product Scientific Advisory Boards (SAB) and Data
and Safety Monitoring Boards (DSMB) for hematology, oncology, and therapeutic candidates. Most recently, Dr. Desai, served as Vice President,
Head of U.S. Medical Affairs – Oncology at Glaxo Smith Kline (GSK). At GSK, he established the U.S. medical affairs oncology
team that oversaw the launch readiness plans for three novel oncology products—Blenrep® in multiple myeloma, Zejula® in
ovarian cancer, and dostarlimab in endometrial cancer. Prior to GSK, Dr. Desai has overseen the clinical development, implementation,
and delivery of oncology life cycle management plans for various oncology therapies at several leading global pharmaceutical companies,
including Eli Lilly & Company (Lilly), Janssen Pharmaceuticals, Inc. and Takeda, Inc. Prior to GSK, he was the VP of Global Medical
Affairs at Lilly, during which time he oversaw the global medical affairs team for Lilly's GI Oncology portfolio. Earlier in his career,
Dr. Desai contributed to the approval of Janssen's myeloma drug Darzalex® (daratumumab) and leading and strategically executing medical
affairs activities globally for Velcade® (bortezomib). Prior to Janssen, Dr. Desai was responsible for the international development
of oncology products in solid tumors and hematological malignancies at Sanofi, where he successfully executed pivotal trials that
led to NDA submission for Jevtana® (cabazitaxel).
In accordance with General Instruction B.2 of
Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed”
for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise
subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the
Securities Act of 1933, as amended, except as shall be expressly set forth by reference in such a filing. Furthermore, the furnishing
of information under Item 7.01 of this Current Report on Form 8-K is not intended to constitute a determination by the Company that
the information contained herein, including the exhibits hereto, is material or that the dissemination of such information is required
by Regulation FD.